StockData
Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock

RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$0.45−0.02 (-4.36%)

Close on Oct 19, 2026Market cap $5.94MP/E –Yield –

Reviva Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Reviva Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$11.88M. For fiscal 2025 it was -$20.20M. The highest annual figure on record is -$376.86K in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$20.20M–
FY2024Dec 31, 2024-$30.80M–
FY2023Dec 31, 2023-$39.50M–
FY2022Dec 31, 2022-$28.23M–
FY2021Dec 31, 2021-$10.10M–
FY2020Dec 31, 2020-$2.43M–
FY2019Dec 31, 2019-$376.86K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.43M–
Q2 FY2026Jun 30, 2026-$2.62M–
Q1 FY2026Mar 31, 2026-$3.27M–
Q4 FY2025Dec 31, 2025-$3.56M–
Q3 FY2025Sep 30, 2025-$4.03M–
Q2 FY2025Jun 30, 2025-$6.07M–
Q1 FY2025Mar 31, 2025-$6.54M–
Q4 FY2024Dec 31, 2024-$6.28M–
Q3 FY2024Sep 30, 2024-$8.46M–
Q2 FY2024Jun 30, 2024-$8.13M–
Q1 FY2024Mar 31, 2024-$7.92M–
Q4 FY2023Dec 31, 2023-$9.62M–
Q3 FY2023Sep 30, 2023-$11.56M–
Q2 FY2023Jun 30, 2023-$11.34M–
Q1 FY2023Mar 31, 2023-$6.98M–
Q4 FY2022Dec 31, 2022-$8.89M–
Q3 FY2022Sep 30, 2022-$5.50M–
Q2 FY2022Jun 30, 2022-$5.52M–
Q1 FY2022Mar 31, 2022-$7.45M–
Q4 FY2021Dec 31, 2021-$3.96M–
Q3 FY2021Sep 30, 2021-$2.48M–
Q2 FY2021Jun 30, 2021-$1.79M–
Q1 FY2021Mar 31, 2021-$1.87M–
Q3 FY2020Nov 30, 2020-$352.01K–
Q2 FY2020Aug 31, 2020-$525.92K–
Q3 FY2019Nov 30, 2019-$166.02K–
Q2 FY2019Aug 31, 2019-$94.11K–
Q3 FY2018Nov 30, 2018-$79.15K–
Q2 FY2018Aug 31, 2018-$15.67K–

More Reviva Pharmaceuticals figures

See a number that looks wrong?